Pharmaceuticals & Clinical Research Reservations open Page created Nov 16, 2026

List of Companies Recruiting Patients for Rare Disease Trials

Industry sponsors of rare disease clinical trials that are currently open for enrollment on ClinicalTrials.gov, grouped by company with the conditions, phases and trial IDs they are recruiting for — a prospect list for patient recruitment vendors, advocacy partnership teams and CRO business development.

Fields we plan to include

Sponsor Company
Rare Disease / Condition
Trial ID (NCT Number)
Trial Phase
Number of Recruiting Trials
Recruiting Countries
Intervention Type
Target Enrollment
Study Start Date
Company Website
Headquarters Country

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
Sponsor CompanyRare DiseaseTrial IDPhase
Aspa TherapeuticsSourceCanavan DiseaseNCT04998396Phase 1/Phase 2
Stealth BioTherapeutics Inc.SourceBarth SyndromeNCT07531251Phase 4
Hemab ApSSourceGlanzmann ThrombastheniaNCT07935356Phase 3
Solid Biosciences Inc.SourceFriedreich's AtaxiaNCT07180355Phase 1
YolTech Therapeutics Co., LtdSourcePrimary Hyperoxaluria Type 1NCT07587021Phase 2

Estimated ~600 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

Who is recruiting patients for rare disease trials

Rare disease development is dominated by small and mid-sized biotechs: a company often runs one or two pivotal programs in a single ultra-rare indication, has no in-house patient-finding infrastructure, and depends on a handful of expert centers and patient organizations for every enrolled participant. That makes the sponsor, not the site, the natural buyer of recruitment, pre-screening, genetic testing partnerships and patient-advocacy outreach services.

Where the data comes from

Applicable clinical trials of FDA-regulated drugs and devices must be registered on ClinicalTrials.gov under FDAAA 801, and many European and Asian sponsors register there in addition to the EU Clinical Trials Information System (CTIS) or national registries. Each record carries a lead sponsor name, a sponsor class (Industry, NIH, Other, Network), the overall recruitment status, the conditions studied, the phase and the participating locations. The study record, not a press release, is the authoritative signal that enrollment is open.

As an illustration of scale: on 16 November 2026, a ClinicalTrials.gov query for studies with an Industry lead sponsor, status Recruiting, and the words rare, orphan, inborn errors or gene therapy anywhere in the record returned 463 studies from 282 distinct lead sponsors. Keyword matching misses many orphan indications that are never labelled “rare” in the record (for example hemophilia, Duchenne muscular dystrophy or specific lysosomal storage disorders), which is why the full population of sponsors is materially larger and is best estimated by matching conditions against the Orphanet nomenclature or FDA orphan designations.

Why sponsor-level grouping matters

The registry is organized per study. The same company can appear under a parent name, a local subsidiary or a US affiliate, so sponsor names have to be resolved to one company before trials can be counted. For business development, what matters is the company: how many rare disease studies it is enrolling at once, in which countries, and at which phase. A sponsor with a Phase 3 study in an ultra-rare disease and sites in a dozen countries has a very different recruitment problem from a Phase 1 gene therapy program enrolling a few children at one center.

PhaseTypical rare disease enrollmentRecruitment pain point
Phase 1 / 1-2Single digits to a few dozenFinding genetically confirmed patients who meet narrow age and severity criteria
Phase 2Tens of patientsActivating enough expert sites; natural-history comparators
Phase 3Dozens to low hundredsMulti-country feasibility, travel support, competition with other sponsors for the same patients
Phase 4 / registriesVariesLong-term follow-up and retention of treated patients

Signals that a sponsor needs recruitment help

  • Multiple recruiting studies in the same indication — the sponsor is competing with itself for a tiny patient pool.
  • Start dates well in the past while status remains Recruiting — enrollment is slower than planned.
  • Few listed locations — site footprint is thin and there may be room for additional sites or decentralized options.
  • Pediatric gene therapy programs — eligibility often requires newborn screening or genetic testing partnerships to identify patients early.
  • Orphan indications with an active patient organization — advocacy partnerships can shorten the path to eligible families.

How to read a study record

The ClinicalTrials.gov record shows the overall status (Not yet recruiting, Recruiting, Enrolling by invitation, Active not recruiting, Completed), and status changes are submitted by the sponsor, so a record can lag reality by weeks. Check the “Last update posted” date and the per-location recruitment status before outreach, and cross-reference the EU CTIS entry for European trials, which publishes country-level authorization dates.

A recruiting rare disease study is a time-boxed opportunity: once enrollment closes, the sponsor’s budget for patient-finding moves to the next program.

Frequently Asked Questions

Q.What counts as a rare disease for clinical trial purposes?

In the United States a rare disease affects fewer than 200,000 people (Orphan Drug Act); in the European Union the threshold is no more than 5 in 10,000 people. Orphanet catalogues more than 6,000 rare diseases, most of them genetic and many first appearing in childhood.

Q.Why is patient recruitment harder in rare disease trials?

Eligible patients are few and geographically scattered, many are undiagnosed or lack a confirmed genetic diagnosis, expert centers are limited, and several sponsors may target the same small population at once. Sponsors therefore rely on patient organizations, genetic testing programs, registries and travel support to reach enrollment targets.

Q.How do orphan drug designations relate to recruiting trials?

Orphan designation from the FDA or EMA is granted to a product for a rare condition and brings incentives such as market exclusivity and fee reductions. Designation can be granted before or during clinical development, so many designated products have trials enrolling patients, but a designation alone does not mean a trial is open.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.